We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Search for Drugs to Treat Spinal Muscular Atrophy Pinpoints Likely Target Enzyme

By LabMedica International staff writers
Posted on 02 Mar 2016
Print article
Image: From left to right: Microscopic images comparing the hind leg muscles of normal mice, mice with spinal muscular atrophy, and mice with spinal muscular atrophy that have had the enzyme Jnk3 inhibited. Jnk3 deficiency appears to reduce muscle degeneration (muscle-wasting) and increase muscle growth in mice with the disease (Photo courtesy of the journal Human Molecular Genetics).
Image: From left to right: Microscopic images comparing the hind leg muscles of normal mice, mice with spinal muscular atrophy, and mice with spinal muscular atrophy that have had the enzyme Jnk3 inhibited. Jnk3 deficiency appears to reduce muscle degeneration (muscle-wasting) and increase muscle growth in mice with the disease (Photo courtesy of the journal Human Molecular Genetics).
Neurological disease researchers have identified a target for drugs to treat the hereditary childhood neurodegenerative disorder spinal muscular atrophy (SMA).

SMA is caused by a mutation in the SMN1 (survival motor neuron 1) gene. SMN1 deficiency causes spinal motor neuron degeneration, which results in progressive muscle atrophy and death. The molecular mechanism underlying neurodegeneration in SMA is unknown, and no treatment is currently available to prevent neurodegeneration and reduce the burden of illness.

Investigators at the Texas Tech University Health Sciences Center (El Paso, USA) worked with neuron cultures and mouse models of SMA while searching for possible drug targets that would correct the neurological damage caused by the disorder.

They reported in the December 15, 2015, issue of the journal Human Molecular Genetics that they had identified the c-Jun NH2-terminal kinase (JNK) signaling pathway as being responsible for neurodegeneration in SMA. The neuron-specific protein isoform Jnk3 was required for the neuron degeneration caused by SMN1 deficiency, while lack of Jnk3 reduced degeneration of cultured neurons caused by low levels of SMN1. Genetic inhibition of the JNK pathway in JNK3 knockout mice resulted in relief of SMA symptoms. Jnk3 deficiency prevented the loss of spinal cord motor neurons, reduced muscle degeneration, improved muscle fiber thickness and muscle growth, improved motor function and overall growth and increased lifespan of mice with SMA.

"So far, spinal muscular atrophy research has focused on targeting the genetic mutation to prevent degeneration of spinal motor neurons, but it has not been successful because of challenges associated with gene therapy," said senior author Dr. Laxman Gangwani, associate professor of neurosciences at Texas Tech University Health Sciences Center. "This is the first study done that identifies a target, Jnk3, that is independent of the genetic mutation of spinal muscular atrophy for novel therapeutic development.

"Jnk3 represents a promising new avenue of research for clinical advances in developing a treatment," said Dr. Gangwani. "We saw less muscle degeneration, more muscle growth and better muscle strength, and improvement in overall movement. What were more striking were a four-fold reduction in initial mortality period and a two-fold increase in total lifespan."

Related Links:

Texas Tech University Health Sciences Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.